IPO Date: Mar 24 to Mar 27 2026
Listing Date: Apr 2 2026
1. Capacity expansion and upgradation of manufacturing facilities;
2. Establishment of a new R&D Centre;
3. Repayment / prepayment of certain outstanding borrowings;
4. Working capital requirements;
5. Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and
6. General corporate purposes
Plot No.39, 5th Floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K. V Seri Lingampally
Rangareddy
Telangana
500032
7997991306
cs@saiparenterals.com / info@saiparenterals.com
www.saiparenterals.com
Bigshare Services Pvt Ltd
Pursuant to Regulation 29 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sai Parenterals has informed that the Board Meeting of the Company will be held on Sunday, 01st November, 2026 at the registered office of the Company to consider, the following: 1. Un-audited financial results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. 2. Limited Review Report (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026. 3. Any other business with the permission of the Chair. Further, with reference to our letter dated 30th September, 2026 regarding closure of trading window for dealing in shares of the Company, the company has informed that, pursuant to the Code of Conduct to Regulate, Monitor and Report Trading in Securities of the Company, the trading window shall continue to remain closed for all Designated Persons of the Company and their Immediate Relatives until 48 hours after the declaration of the Un-audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30th September, 2026.
The above information is a part of company’s filings submitted to BSE.
Pursuant to Regulation 30(6) read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Sai Parenterals has informed that the Company has issued a Press Release titled ‘Sai Parenterals Completes the Acquisition of R&D Facility Prathyak Laboratories’.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The issue size of Sai Parenteral's Ltd. IPO is ₹279.84 - 294.88 crore.
The Sai Parenteral's Ltd. IPO opens for subscription on 2026-03-24 and closes on 2026-03-27.
The price range of Sai Parenteral's Ltd. IPO is ₹372.00 to ₹392.00.
The lot size of Sai Parenteral's Ltd. IPO is 38 shares.
The registrar of Sai Parenteral's Ltd. IPO is Bigshare Services Pvt Ltd .
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.